It is time to include patients with brain tumors in phase I trials in oncology

Journal of Clinical Oncology

Volumn 29, Issue 24, 2011, Pages 3211-3213

  Wen, Patrick Y ^a   Schiff, David ^b   Cloughesy, Timothy F ^c   Reardon, David A ^d   Batchelor, Tracy T ^e   Chabner, Bruce A ^e   Flaherty, Keith ^e   De Groot, John F ^f   Gilbert, Mark R ^f   Galanis, Evanthia ^g   Chang, Susan M ^h   Schwartz, Gary K ⁱ   Peereboom, David ^j   Mehta, Minesh P ^k   Yung, W K Alfred ^f   Grossman, Stuart A ^l   Prados, Michael D ^h   DeAngelis, Lisa M ⁱ  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g MAYO CLINIC   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^j LERNER RESEARCH INSTITUTE   (United States)

^k NORTHWESTERN UNIVERSITY   (United States)

^l JOHNS HOPKINS UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBAMAZEPINE; CORTICOSTEROID; ETIRACETAM; HARKOSERIDE; LAMOTRIGINE; PHENYTOIN; PREGABALIN; RITUXIMAB; TEMOZOLOMIDE; TOPIRAMATE;

BLOOD BRAIN BARRIER; BRAIN TUMOR; CANCER PATIENT; CANCER SURVIVAL; DRUG ACTIVITY; DRUG METABOLISM; DRUG PENETRATION; DRUG STRUCTURE; DRUG TARGETING; GLIOBLASTOMA; HUMAN; LIFE EXPECTANCY; LIPOPHILICITY; MAXIMUM TOLERATED DOSE; MOLECULAR WEIGHT; NEUROTOXICITY; NOTE; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL;

BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; CLINICAL TRIALS, PHASE I AS TOPIC; HUMANS; MIDDLE AGED; MOLECULAR TARGETED THERAPY;

EID: 80051984486     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.36.6328     Document Type: Note

References (13)

1. Wen P.Y., Yung W.K., Lamborn K.R., et al: Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res 12:4899-4907, 2006 (Pubitemid 44338577)
2. Raizer J.J., Abrey L.E., Lassman A.B., et al: A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas. Neuro Oncol 12:87-94, 2010
3. Fetell M.R., Grossman S.A., Fisher J.D., et al: Preirradiation paclitaxel in glioblastoma multiforme: Efficacy, pharmacology, and drug interactions-New Approaches to Brain Tumor Therapy Central Nervous System Consortium. J Clin Oncol 15:3121-3128, 1997
4. Lamborn K.R., Yung W.K., Chang S.M., et al: Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol 10:162-170, 2010
5. Wick W., Puduvalli V.K., Chamberlain M.C., et al: Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 28:1168-1174, 2010
6. Friedman H.S., Prados M.D., Wen P.Y., et al: Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733- 4740, 2009
7. Kreisl T.N., Kim L., Moore K., et al: Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27:740-745, 2009
8. Batchelor T.T., Duda D.G., di Tomaso E., et al: Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 28:2817-2823, 2010
9. Batchelor T.T., Grossman S.A., Mikkelsen T., et al: Rituximab monotherapy for patients with recurrent primary CNS lymphoma. Neurology 76:929-930, 2011
10. Cancer Genome Atlas Research Network: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061-1068, 2008
11. Newlands E.S., Blackledge G.R., Slack J.A., et al: Phase I trial of temozolomide (CCRG 81045: M&B 39831: M&B 39831NSC 362856). Br J Cancer 65:287-291, 1992
12. Eisenhauer E.A., Therasse P., Bogaerts J., et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
13. Wen P.Y., Macdonald D.R., Reardon D.A., et al: Updated response assessment criteria for high-grade gliomas: Response assessment in neuro-oncology working group. J Clin Oncol 28:1963-1972, 2010